Codexis, Inc. announced that it has attended the official opening of Porton Pharma Solutions Ltd.'s fermentation pilot laboratory located in Porton's Changshou site, achieving another important milestone in the strategic partnership between Porton and Codexis in the field of biocatalysis technology. The opening of Porton's biocatalysis technology lab and fermentation facility at its Changshou site in Chongqing builds on its previous strategic investments in biocatalysis, and its partnership with Codexis. In 2018, in order to further expand the value adding application of biocatalysis in pharmaceutical processes, Porton and Codexis announced their strategic partnership, and Porton established licensed biocatalysis capabilities at its Shanghai R&D center.

Since then, the partnership has focused on screening biocatalysts against many of Porton's CDMO process opportunities. Porton's new biocatalysis infrastructure in Chongqing adds enzyme development and pilot scale manufacturing to its established high throughput biocatalysis screening expertise. These investments enable the prospect to broaden the application of Codexis' biocatalyst technologies within Porton's global pharmaceutical customer base.